Evaluating the efficacy and safety of SpikoGen®, an Advax-CpG55.2–adjuvanted severe acute respiratory syndrome coronavirus 2 spike protein vaccine: a phase 3 randomized placebo-controlled trial-Reference-Cited by-同舟云学术

Evaluating the efficacy and safety of SpikoGen®, an Advax-CpG55.2–adjuvanted severe acute respiratory syndrome coronavirus 2 spike protein vaccine: a phase 3 randomized placebo-controlled trial

Published:2023-02 Issue:2 Volume:29 Page:215-220
ISSN:1198-743X
Container-title:Clinical Microbiology and Infection
language:en
Short-container-title:Clinical Microbiology and Infection

Author:

Tabarsi Payam,Anjidani Nassim,Shahpari Ramin,Mardani Masoud,Sabzvari Araz,Yazdani Babak,Kafi Hamidreza,Fallah Newsha,Ebrahimi Ali,Taheri Ali,Petrovsky Nikolai,Barati Saghar

Funder

CinnaGen

Publisher

Elsevier BV

Subject

Infectious Diseases,Microbiology (medical),General Medicine

Reference20 articles.

1. Efficacy and safety of Tocilizumab in severe and critical COVID-19: a systematic review and meta-analysis;Rezaei;Expert Rev Clin Immunol,2021

2. Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants;Tseng;Nat Med,2022

3. The how’s and what’s of vaccine reactogenicity;Hervé;NPJ Vaccines,2019

4. Adjuvants for coronavirus vaccines;Liang;Front Immunol,2020

5. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine;Heath;N Engl J Med,2021

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preparation of a novel type I feline coronavirus virus-like particle vaccine and its immunogenicity in mice and cats;Microbial Pathogenesis;2024-09

2. Post-Hoc Analysis of Potential Correlates of Protection of a Recombinant SARS-CoV-2 Spike Protein Extracellular Domain Vaccine Formulated with Advax-CpG55.2-Adjuvant;International Journal of Molecular Sciences;2024-08-30

3. Clinical Microbiology and Infection: how did we do in 2023?;Clinical Microbiology and Infection;2024-07

4. MultiTEP-Based Vaccines Targeting SARS-CoV-2 Spike Protein IgG Epitopes Elicit Robust Binding Antibody Titers with Limited Virus-Neutralizing Activity;Pathogens;2024-06-20

5. Safety and immunogenicity of COReNAPCIN, a SARS-CoV-2 mRNA vaccine, as a fourth heterologous booster in healthy Iranian adults: A double-blind, randomized, placebo-controlled, phase 1 clinical trial with a six-month follow-up;International Immunopharmacology;2024-06